Home
Congressional Testimony

Presented to Members of The House International
Relations Committee Subcommittee on Africa, Global
Human Rights, and International Operations

Written Testimony
of William D. Moeller

President, American Biotech Laboratories
80 West Canyon Crest Roa
d
Alpine, Utah 84004

April 26, 2005

Written Testimony of William D. Moeller

President, American Biotech Laboratories

80 West Canyon Crest Road

Alpine, Utah 84004

Presented to Members of The House International Relations Committee Subcommittee on Africa, Global Human Rights, and International Operations

April 26,2005

INTRODUCTION

Good Morning. I am William D. Moeller, Chairman and President of American Biotech Laboratories of Alpine, Utah ("ABL"), a company which produces engineered, metallic silver, nano-sized particles in water-based products. Our engineered silver particles have performed far beyond anyone's expectations as anti-microbial agents, against a staggering variety of microbes such as malaria, flesh-eating bacteria (MRSA - Methicillin Resistant Staphylococcus aureus) and E.coli.

Whether used on surfaces as disinfectants or if taken internally as supplements, all of our ABL products are non-toxic and have no known adverse human side effects. Our products have surprised many experts in the medical and science worlds because of their ability to combat bacteria, yeast, and viruses. ABL products have been proven to destroy anthrax spores and bubonic plague bacteria on surfaces, to eliminate the malaria parasite in humans and a host of other beneficial results.

We have developed five products to date as well as several other new products currently in our product development pipeline. We manufacture all of our products in the United States. One product ASAP-AGX-32 (a water solution containing 32 ppm of our engineered silver nano-particles) has already been approved by the EPA as a surface disinfectant for hard, non-porous surfaces in commercial, residential, industrial, hospital and medical environments. Another product called Silgel is a non-toxic moisturizing gel, which utilizes our ASAP-AGX-32 as a raw material supply of silver particles. It is currently undergoing the final steps for FDA approval for the treatment of lacerations, first and second degree burns, abrasions, surgical wounds, skin ulcers etc. Several other new ABL products will soon warrant the filing of new FDA and/or USDA applications.

BACKGROUND

All my life I have been involved with the mining and processing of silver in Utah. I am Chairman of the Board of Clifton Mining, a Utah mining company holding several million ounces of silver reserves. My family and I are large stockholders in Clifton Mining. I have spent most of my life in Utah where my wife Jeneane and I raised our seven children together.

In the late 1990s, the price of silver reached a point where its mining and production costs were above its selling price. At that time, we needed to find an alternative use for silver that at least paid for removing the silver from the rock ore. We decided to devote some the resources of Clifton mining to try to create a new water-based product containing silver. Since ancient times it has been known that silver inherently possesses desirable antimicrobial and immune boosting properties. We planned to be the first to maximize those desirable effects of silver. We did our homework and found a plethora of colloidal silver products and devices littering the marketplace, most of which did not seem very sophisticated to us. Our analyses of various colloidal silver products (mainly dietary supplements) led us to the conclusion that these manufacturers lacked stature in the marketplace and the products produced were, at best, anecdotally effective.

In 1998 we created ABL with the idea of manufacturing high quality, standardized colloidal silver products. I talked all five of my sons into joining ABL in what we thought might be a nice family business. We worked hard inventing new methods to purify and standardize our silver products and, frankly, got a little lucky along the way because we ended up inventing and manufacturing something else all altogether.

Our initial discoveries are the subject of two issued US Patents: 6,214,299, which issued on April 10, 2001 and related US Patent 6,743,348, which issued on June 1,2004 (See Appendix 1). Additional discoveries are contained in several other pending patent applications, most of which are not yet in the public domain.

Although ABL's initial products were referred to as "colloidal silver," we now know that our engineered particles are quite different. When most people use the phrase "colloidal silver," they mean ionic silver, silver salts or silver nitrate in a gelatin matrix. ABL's liquid products do not contain ionic silver, silver salts or silver nitrates. Rather, they contain engineered nano-sized particles of metallic silver dispersed in a matrix of pure water. Although these products are primarily water (99.999%)

because the actual silver concentration is so low. Their unique potency has been demonstrated by numerous laboratory (in vitro) and human (in vivo) tests carried out by ABL, at ABL's request, and in some of the most interesting cases, without ABL's involvement or even contemporaneous knowledge.

ABL's first three products that we manufactured were dietary supplements. These products have actual silver concentrations of 10 parts per million ("ppm"), 14 ppm and 22 ppm and are sold through a number of different outlets. For example, ASAP 10 (the 10 ppm product) is being sold through General Nutrition Center stores throughout the country under the name Silver Biotics. This 10 ppm of silver particles in purified water is colorless, tasteless, odorless and is non-toxic. Based on our knowledge of the engineering of the metallic silver particles, we estimate the actual shelf life of our products to be in excess of 10 years.

As demand for our products grew, we began distributing ASAP 10 worldwide. In short order, many different positive antidotal stories began to pour in from around the world. The interest in our product grows and certain private investors joined our core "family and friends" group. One user's experience led to an important event that would forever open our eyes to the power of our 10 ppm ASAP non-toxic liquid.

In 2001, twelve bottles of our 10 ppm ASAP product fell into the hands of a medical Doctor in Rwanda, Dr. Ewabuhihl Ezechias. One day I received a frantic telephone call from Dr. Ezechias' office that was in Rwanda caring for a group of very young children who were in the last stages of malaria about to die. Dr. Ezechias was looking for instructions on how to administer our ASAP 10 product to these desperately ill children. I suggested to the Doctor that he measure out a teaspoon or two to each of the children, two or three times a day and that he repeat the process until the children hopefully showed some improvement. He responded abruptly that there was no time for measuring anything - the situation was far too grave for "such niceties." All of these children had temperatures around 105 degrees, had not improved with conventional treatments and were all about to die. He asked me if he could simply put the water into their bottles. Knowing of its totally non-toxic properties and sensing his desperation, I assured him that it would not hurt the children.

Days later, Dr. Ezechias contacted and told me that he had put the ASAP 10 ppm water directly into the drinking water bottles of 11 of these children. All 11 of the young children who received the ASAP 10 ppm got better. A week later, the 11 left his clinic alive and healthy. Sadly, there were other children

who did not receive the ASAP treatment. Those children died in spite of receiving all the conventional treatments which Dr. Ezechias provided them. This affected me deeply and I realized that our ASAP 10 ppm had potent, positive effects on malaria patients. Besides the phone calls, we also received an indirect written communication from Rwanda which is included in Appendix 2.

Word spread quickly and soon scientists and medical doctors from around the world began to hear stories about ABL's silver products. One doctor from Mumbai, India, Dr. Dilip Mehta of Viridis BioPharma decided to check out the many stories. Without our knowledge, he began to test our products in a variety of different ways against several different micro-organisms. Dr. Mehta scientifically tested and compared our products with other silver-based products from around the world. Dr. Mehta concluded that no other product in the world had the biological efficacy of our non-toxic ASAP 10 ppm product. Traveling half-way around the world from India to Utah, Dr. Mehta unexpectedly showed up at our Alpine facility to begin a trusted and fruitful association advancing our knowledge and product base.

We also have met many important scientists along our journey, including Professor Rustum Roy who concurrently holds appointments with Pennsylvania State University, Arizona State University, and the University of Arizona. Professor Roy is a world leading materials scientist (please refer to www.rustumroy.com) whose initial interest was in determining and characterizing the physical properties of our water products. Because he was interested in water and its relationship to general health, Professor Roy wanted to correlate physical properties of ABL's water-based silver products with their superior biological performance. He found that our ASAP 10 and ASAP-AGX-32 water-based products are physically quite different in a number of inherent, measurable, physical properties from colloidal silver products. Professor Roy has now generated much data showing that our products are unique. Professor Roy has presented this data at several scientific conferences. Please see Professor Roy's letter in Appendix 3.

Professor Roy, in turn, introduced us to General Resonance, a cutting-edge science and technology company located in Maryland, whose work and expertise Professor Roy had scrutinized and tested at the Materials Research Laboratory at Perm State. ABL and General Resonance recognized their potential synergy and have formed a joint venture. The combination of General Resonance's fundamental understandings and its patented sciences and technologies with ABL's existing products and technologies promises to generate a long-lasting pipeline of new, more potent products with a

THE TECHNOLOGY

ABL manufactures its water-based products by controlling and delivering a few thousand Volts AC through highly purified silver electrodes in contact with the surface of high purity water. The silver in the electrodes is slowly dispersed into the water as metallic silver nano-sized particles. These engineered silver particles currently vary in size between about 10-50 nanometers in diameter, depending on the particular manufacturing conditions. Concentrations as low as 1-2 ppm have been shown to have efficacy against certain bacteria and viruses, however, the products being sold right now typically range in concentration of from 10 ppm - 32 ppm (i.e. ASAP 10 and AGX 32, both of which are greater than 99.999% pure water). These concentrations have been shown to kill or de-activate bacteria and viruses in a few minutes. Appendix 4 shows in brief summary form certain in vitro results and data which demonstrate the broad spectrum efficacy of ABL silver-water solutions against a variety of microbes (and related human diseases).

The data in Appendix 4 (along with other data not presented today) suggest that small amounts of selectively engineered silver particles can have dramatic anti-bacterial, anti-fungal, and anti-viral effects. Surface disinfectants (e.g., bleach) and most pharmaceutical products against these agents of disease function by various chemical reactions and are consumed and used up in the process. These agents that are consumed in this way must be replenished to remain effective. Our silver particles function differently and it is clear from ongoing research that our engineered silver particles are not consumed in chemical reactions the way other anti-microbial agents are. Rather, it appears that the silver particles function as catalysts, which promote certain lethal reactions in only unfriendly microbes (i.e., the destruction of bacteria, fungi and viruses). This is the same way platinum particles in an automobile's catalytic converter function. They promote lethal reactions in pollutants without being consumed in the process. We believe that this understanding is very important and partly explains the lack of any known negative biological side effects from the ABL products. If engineered properly, very small amounts of catalytic silver apparently can go a very long way.

MALARIA STUDIES

After ABL learned how the lives of the 11 young children in Rwanda were saved (discussed above) ABL initiated contact with four different hospitals/clinics in Ghana. We shipped to these different medical facilities about 1000 of our 8 ounce bottles of ASAP 10. Obtaining good follow-up clinical data turned out to be quite difficult because once the patients felt better; they simply did not come back for further treatment and follow-up. For example, Appendix 5 contains representative data from the Justub Clinic, run by Dr. Agnes Abraham, who reported after her first trials, that typically their patients return to the clinic only if they are still ill, which was not the case with their patients treated with the ASAP 10.

Another preliminary trial occurred at the Air Force Hospital in Ghana where the Medical Officer in Charge was Dr. Evelyn Kwabiah. The five patients treated by Dr. Kwabiah all had positive outcomes (see Appendix 6). Dr. Kwabiah reported that patients with malaria who had received the ASAP 10: recovered faster than those receiving conventional treatments; recovered where conventional treatments had failed; or, that the ASAP 10 functioned as a prophylactic preventing the recurrence of malaria.

Ultimately, the success of ABL's ASAP 10 ppm against malaria gained such widespread acceptance in Ghana that the Food and Drugs Board of the Republic of Ghana issued a Certificate of Registration of a Drug for ABL's product (see Appendix 7).

Although we were receiving better clinical reporting, and Ghana had issued a Certificate of Registration, we still were not satisfied that the previous trials met the level of standardization we wanted to achieve. To obtain better data concerning ASAP 10's effectiveness against malaria, ABL (in cooperation with competent university medical professionals) designed a new protocol (see Appendix 8). The new protocol required that all Malaria patients be monitored for 15 days and were encouraged to return for follow-up testing and assessment with financial incentives (patients were paid a few dollars a day to come back and be monitored and tested). Appendix 8 contains the study protocol, results, and one representative patient's chart. (An Executive Summary of these more reliably executed Malaria Studies in Ghana, supported by ABL, is shown in Appendix 9).

Study #3 listed in Appendix 9 was the most reliable of the studies and used the protocol described in Appendix 8. The data showed that out of the 41 Malaria patients (ages 1-90 years) involved in the studies and receiving ASAP 10, all 41 people survived and there were no treatment failures. All

participating patients were deemed to have achieved full recovery in an average of 4.5 to 6.5 days, with recovery time differences probably being due in part to differences in total dosages. Clearly the data suggest that ABL's ASAP 10 ppm product, when administered in 2-3 teaspoon quantities 2-3 times per day (i.e., one ounce per day) reverses malaria and saves lives. The cost of this regimen in total is a few dollars and appears to be highly effective.

No undesirable or drug-like side effects were reported by any of the patients in any of these more rigorous studies. We believe that this was because the ASAP 10 ppm is primarily water with very small amounts of catalyst-like metallic silver particles therein,. This result is also quite different from all other known malaria treatments, which often involve quite uncomfortable side effects.

ABL has continued its efforts to determine the effectiveness of its ASAP 10 ppm product as an effective treatment against malaria. To that end, ABL sought the input of various malaria experts including that of Dr. Awa Marie Coll-Seck, Executive Secretary of the Roll Back Malaria Partnership hosted by the World Health Organization. Dr. Coll-Seck provided her comments which were instrumental in creating a proposed 660 patient study; initially to be performed in Senegal. This Protocol was just completed earlier this month, but has not yet been initiated. ABL hopes to be able to accomplish this or a similar study in the near future so that we can begin to have a larger impact on malaria worldwide.

TUBERCULOSIS

Preliminary data generated by two independent laboratories suggest an efficacy of ASAP 10 ppm and AS AP-AGX-32 against tuberculosis. But, because this data is new and not yet reviewed, we are reluctant to share any of the data at this time. However, we are encouraged by what we have seen.

OTHER PRODUCTS OF INTEREST

1. Surface Disinfectant.

ABL received EPA approval for ASAP-AGX-32 in 2003 (see Appendix 10). ABL also received a contract (Contract No. V797P-5762X) with the VA Hospitals, to use this product as a surface

disinfectant. Appendix 11 shows data recently generated by an independent laboratory comparing AGX-32 to eight leading disinfectants for use against Methicillin resistant Staphylococcus aureus (MRSA). The data is reported two different ways: (1). "% Effectiveness," which compares how effective the leading disinfectant is compared to AGX-32 (e.g., "Phenol" is 40% as effective as AGX-32); and (2) "Coefficient," which shows the reverse or how much better AGX-32 is relative to the leading disinfectant (e.g., AGX-32 is 2.5 times more effective than Phenol). These data are very significant because AGX-32 is a non-toxic product, unlike most disinfectants, and yet functions as well or better than the other disinfectants. It can be used around hospitalized patients without any ill effects. Moreover, because the silver functions akin to a catalyst, it is not consumed in a chemical process and will continue to disinfect a surface until removed (e.g., by soap and water) from the surface on which it was applied.

2. Wound Care and Burn Care.

ABL has a 510(k) application pending with the FDA (see Appendix 12) for AGX SILGEL, a moisturizing gel containing ABL engineered silver particles. ABL expects the final animal study required for this FDA approval for wound care to be finished in June 2005. We anticipate that approval will be obtained for use of the SILGEL silver-gel product on: lacerations, abrasions, skin tears, leg and other surface ulcers, surgical wounds, first and second degree burns etc. The base material for manufacturing this product is ASAP-AGX-32 (a non-toxic precursor). This AGX SILGEL product is a broad spectrum, anti-microbial. SILGEL is not cytotoxic in studies performed to date (e.g., the gel has been proven to be non-toxic in the oral route, by mouse model studies up to 5000mg/kg of body weight). ABL's silver-gel provides moisture for wound healing and burn treatment, has no color or smell, requires no refrigeration and remains stable from 17-113 degrees Fahrenheit. In FDA approval comparison studies, AGX SILGEL was found to be over 10 times more effective in killing MRS A compared to a leading FDA approved silver-based product (at a challenge of about 10,000,000 bacteria/ml), even though the leading and approved product contains more than 300 times as much silver than AGX SILGEL.'

1 This product has not been offered for sale due to the pending FDA Application.

Dr. John A. Shaw, a practicing oncologist in Arizona, has recently been using AGX Silgel on an experimental basis to treat radiation burns from radiation therapy used for treating breast cancer. His reviewed work has been conducted at hospitals in Arizona. His initial findings are that the AGX Silgel promotes healing more effectively than other commercially available products. A letter from Dr. Shaw is included in Appendix 13.

GOVERNMENT ACTIVITIES OF INTEREST

ABL has initiated a number of recent US Government contacts, which have resulted in the testing of ASAP-AGX-32 and AGX Silgel products (or at least the desire to test). Many of these contacts have generated desirable data showing the efficacy of ABL's products for different uses. We have not offered these products for sale to the government yet.

Letters of support for ABL from Senator Orrin Hatch and Lt. General Paul K. Carlton, Jr., addressed to The Honorable Tom Ridge, can be found in Appendix 14.

CONCLUDING STATEMENT

ABL has invented and patented a process and a product that should have wide applicability to a variety of bacterial, fungal and viral species. The production process is robust and can be quickly scaled-up to meet virtually any production demands. The ASAP 10 ppm product, in quantities of about 1 ounce per day, seems to eliminate the symptoms of malaria in human patients in about 4-6 days. Thus, one 8 ounce bottle of ABL's ASAP 10 ppm has been more than enough to eliminate the symptoms of malaria in each of the patients involved in the African studies. ABL is ready to make this product (or the process) available on a world-wide basis. We hope that the Committee will be sufficiently impressed to help us to help others.


Appendix 2

Appendix 3

Appendix 4

Disease                                                                  Pathogen                                   Effective Concentration

Boils                                                           Staphylococcus aureus                                   Killed @ 5 ppm

Osteomyelitis                                             Staphylococcus aureus                                   Killed @ 5 ppm

Bacillary Dysentery                                     Shigella boydii                                                 Killed @ 2.5 ppm

Burn Infections                                            Pseudomonas aeruginosa                               Killed @ 5 ppm

Dental Plaque                                             Streptococcus mutans                                     Killed @ 5 ppm

Diarrhea (Bloody)                                        Shigella boydii                                                 Killed @ 2.5 ppm

Diarrhea                                                     Escherichia coli                                               Killed @ 2.5 ppm

Ear Infection                                               Haemophilus influenzae                                  Killed @ 1.25 ppm

Ear Infection                                               Streptococcus pneumonie                               Killed @ 2.5 ppm

Enteric Fever                                              Salmonella tyhimurium                                    Killed @ 2.5 ppm

Epiglottitis (In children)                                Haemophilus influenzae                                  Killed @ 1.25 ppm

Eye Infections                                            Staphylococcus aureus                                   Killed @ 5 ppm

Corneal Ulcers-Keratitls                             Pseudomonas aeruginosa                               Killed @ 5 ppm

Food Poisoning                                          Salmonella arizona                                          Killed @ 5 ppm

Food Poisoning                                         Salmonella tyhimurium                                    Killed @ 2.5 ppm

Food Poisoning                                          Escherichia coli                                               Killed @ 2.5 ppm

Endocarditis                                               Streptococcus faecalis                                    Killed @ 2.5 ppm

Endocarditis                                                Streptococcus gordontl                                    Killed @ 5 ppm

Meningitis                                                    Haemophilus influenzae                                  Killed @ 1.25 ppm

Meningitis                                                  Enterobacter aerogenes                                  Killed @ 2.5 ppm

Meningitis                                                  Pseudomonas aeruginosa                               Killed @ 5 ppm

Meningitis                                                  Streptococcus pneumonie                               Killed @ 2.5 ppm

Nosocomial Infections                                  Klebsiella pneumoniae                                    Killed @ 2.5 ppm

Nosocomial Infections                                 Pseudomonas aeruginosa                               Killed @ 5 ppm

Nosocomial Infections (From hospitals)        Streptococcus pyogenes                                 Killed @ 1.25 ppm 

Pneumonia                                                  Staphylococcus aureus                                   Killed @ 5 ppm

Pneumonia                                                  Haemophilus influenzae                                  Killed @ 1.25 ppm

Pneumonia                                                 Pseudomonas aeruginosa                               Killed @ 5 ppm

Pneumonia                                                 Streptococcus pneumonie                               Killed @ 2.5 ppm

Respiratory Tract Infections                        Streptococcus pyogenes                                 Killed @ 1.25 ppm

Respiratory Tract Infections                        E. coli                                                              Killed @ 2.5 ppm .

Respiratory Tract Infections                        Klebsiella pneumoniae                                    Killed @ 2.5 ppm

Scarlet Fever                                             Streptococcus pyogenes                                 Killed @ 1.25 ppm

Septicemia                                                Enterobacter aerpyogenes                              Killed @ 2.5 ppm

Sinus Infections                                         Haemophilus influenzae                                  Killed @ 1.25 ppm

Sinusitis                                                    Streptococcus pneumonie                               Killed @ 2.5 ppm

Impetigo                                                    Staphylococcus aureus                                   Killed @ 1.25 ppm

Skin Infections                                           Staphylococcus aureus                                   Killed @ 5 ppm

Skin Infections                                           Streptococcus pyogenes                                 Killed @ 1.25 ppm

Strep Throat                                              Streptococcus pyogenes                                 Killed @ 1.25 ppm

Suppurative Arthritis                                  Haemophilus Influenzae                                  Killed @ 1.25 ppm

Throat Infections                                        Haemophilus influenzae                                  Killed @ 1.25 ppm

Tooth Decay                                              Streptococcus mutans                                     Killed @ 5 ppm

Urethritis (Men)                                          Trichomonas vaginalis                                     Killed @ 10 ppm

Urinary Tract Infections                              E. Coli                                                               Killed @ 2.5 ppm

Urinary Tract Infections                              Klebsiella pneumoniae                                    Killed @ 2.5 ppm

Urinary Tract Infections                               Pseudomonas aeruginosa                               Killed @ 5 ppm

Urinary Tract Infections                              Streptococcus faecalis                                     Killed @ 2.5 ppm

Urinary Tract Infections                             Enterobacter aerpyogenes                              Killed @ 2.5 ppm

Vaginitis (Women)                                      Trichomonas vaginalis                                     Killed @ 10 ppm

Wound infections                                       Escherichia coli                                               Killed @ 2.5 ppm

Wound Infections                                       Enterobacter aerpyogenes                              Killed @ 2.5 ppm

Wound Infections                                       Klebsiella pneumoniae                                    Killed @ 2.5 ppm

Wound Infections                                       Pseudomonas aeruginosa                               Killed @ 5 ppm

Wound Infections                                       Streptococcus faecalis                                    Killed @ 2.5 ppm

Yeast Infections                                        Candida albicans                                          Killed @ 10 ppm

Appendix 5

Appendix 6

Appendix 7

Appendix 8

PROTOCOL FOR TESTING ASAP SOLUTION (10ppm) IN THE
TREATMENT OF MALARIA

American Biotech Labs, Alpine, Utah
Manufacturer of American Silver's Anti-Bacterial
Product (ASAP)

The purpose of this protocol is to devise a procedure whereby the ASAP Silver Solution produced by American Technology Laboratories can be tested for its' curative properties in treating patients who have contracted a Malaria infection with any of the four (4) Plasmodium species. An overview of the protocol is as follows:

The testing shall be carried out in medical clinics or hospitals which are equipped with or have access to laboratory facilities for the specified test and by medical Doctors who are familiar with the disease and its health ramifications. There will be a total of 16 patients examined per doctor, and the patients will be required to take the silver product twice a day for five days, as well as have their blood drawn one day before the trial begins, and then every day until the blood test shows that the parasite has been eliminated for at least two days. The patients will only be paid if they adhere completely to the schedule for taking the silver and for obtaining the daily blood tests; if they conscientiously follow the requirements for the protocol, the patients who volunteer will be compensated at a negotiated daily rate for each day in the period on total compliance with the protocol specified for the complete test, ie, they take the silver each of the five days as instructed, and that they come in each day as required to have their blood tested for the presence of the malarial parasite. Details of Protocol:

Number of patients to be tested per physicians 16; 8 males and 8 females

Total number of days for the trial: 15

Dose of ASAP Silver Solution {10 ppm) to be given for treatment of patients: A total daily dose of one ounce of ASAP Silver Solution {10 ppm) divided into two equal doses;-one-half ounce {3 tsp) taken in the morning and one-half ounce t3 tap) taken in the evening. The patients will be treated with the ASAP Silver Solution for the first five (5) days of the total 15 day trial, or if the parasite is not completely gone by day five, silver treatment will continue until the parasite is gone, on until day 15, which ever occurs first.

In the event of a patient whose parasites are gone by day two or three, the silver will be continued until day five, and a note made in the records as when the parasite was completely gone.

In the event of a patient who is still harboring parasite after having taken the silver for 15 days, the trial will be terminated as usual, and this patient recorded as a failure to cure in the records.

For the patient who is cured in less than five days, the date of complete parasite disappearance is recorded, the patient continues to receive silver until day five, and continue in the trial to day 15.

Blood tests:

Blood tests to be used: The presence (or absence) of parasites in the patients blood will be determined by either the Acridine Orange stain test, or the Giemsa stain test, on thin or thick blood smears from each of the patients. The patients blood will be tested on day zero (0) to ascertain that they do, in fact, have an active case of malaria. If the blood test confirms an active case of malaria, then that patient will be screened for acceptance into the trial. Screening will include recording of vital data such as name, age, patient reported onset of disease, informing the patient of what will be required of them during the trial, what they will be paid for full compliance, and the fact that failure of compliance will result in being dropped from the trial with no remuneration. For patient that agree to joining the trial, they will be given a written set of instructions telling them how to take the silver product each day, where to go each day for their blood tests, and emphasizing the necessity of complete adherence to the protocol of the trial in order to be paid for any of the days. Include in these written instructions what they will be paid if they successfully do everything required of them in the trial.

Remuneration of physicians: Each physician will be paid a total of $1000.00 (dollars).

When all appropriately kept and signed records have been received by American Biotechnology Labs representatives in Ghana.

The attached form has been proposed for the recording of the test results over the fifteen continuous day's period specified for the test. Observations made in cases of other multiple infections in the course of the treatment of the patience infected with malaria, may be recorded at the back of the form provided. Elaborations or clarifications on the malaria treatment results may also be recorded at the back of the report form.

Appendix 9

Malaria Studies Executive Summary

(This data is intended for government and military use only.)

Introduction

Three human studies on Malaria have now been completed using American Biotech Labs ASAP Solution. The three studies summarized herein, took place in four hospitals in Ghana, West Africa, The first two tests were completed as part of larger more general studies, that were designed to test the product on a variety of human diseases, and to establish effective dosages. Only the work on Malaria is summarized herein. The third study was completed under strict protocols, and was completed with the direct intent to study the effectivity of a specific dose of the ASAP Solution product on human cases of Malaria. The third study was completed with all patients receiving the exact same dosage of the product, under the same time-frames and with their blood checked daily for the existence and levels of the Malaria parasite. American Biotech Labs has three more protocol controlled, human Malaria studies currently underway in two different countries of Africa. The three additional studies are expected to be completed within the next 60 days.

Study # 1

*  Number of participants in the study: (11).

*  Age range of study patients youngest/oldest: (8/75 years).

*  Sex of participants male/female: NA.

*  Average dosage of ASAP Solution given daily: 10 ml (two teaspoons) three times daily.

*  Average number of days until improvement was noted by the doctors: (2.4 days).

*  Average number of days of product usage to achieve full recovery as deemed by the doctors:(5.0 days).

*  Shortest recovery time reported for full recovery: (3 days).

*  Longest recovery time reported for full recovery: (7 days).

*  Number of patients whose blood was checked (post treatment) for the existence of the Malaria Plasmodium: none.

*  Number of treatment failures that occurred in the study: (0) There were no treatment failures!

Study # 2

*  Number of participants in the study: (16).

*  Age range of study patients youngest/oldest: (1/90 years).

*  Sex of participants male/female: NA.

*  Average dosage of ASAP Solution given daily: 5ml (one teaspoon) three times daily.

*  Average number of days of product usage to achieve full recovery as deemed by the doctors:

(6.33 days).

*  Shortest recovery time reported for full recovery: (3 days).

*  Longest recovery time reported for full recovery: (10 days).

*  Number of patients whose blood was checked (post treatment) for the existence of the Malaria Plasmodium: (7 patients).

*  Number of checked patients whose blood tested negative for the Malaria Plasmodium: all seven patients that were checked were found to be completely negative for the Plasmodium.

*  Number of treatment failures that occurred in the study: (0) there were no treatment failures!

Study # 3

*  Number of participants in the study: (16).

*  Age range of study patients youngest/oldest: (2/61 years).

*  Sex of participants male/female: (8/8)

*  Dosage of ASAP Solution given daily: 15ml. (Three teaspoons) given twice daily.

*  Average number of days until no MPS were found in the blood (tested daily): (3.43 days)

*  Average number of days of product usage to achieve full recovery as deemed by the doctors: (4.31 days)

*  Shortest recovery time reported for full recovery: (2 days).

*  Longest recovery time reported for full recovery: (8 days).

*  Number of patients whose blood was checked (post treatment) for the existence of the Malaria Plasmodium: all patients were checked daily for 14 days.

*  Number of checked patients whose blood tested negative for the Malaria Plasmodium: all patients tested negative for the Plasmodium within 6 days.

*  Number of treatment failures that occurred in the study: There were no treatment failures!

Conclusion

All three human studies were deemed to be mil treatment successes. A total of 41 Malaria patients were studied in the three human studies. There were no treatment failures in the studies. All participating patients were deemed to have achieved full recovered from the Malaria disease in averages of 4.5 to 6.5 days, with the theorized difference being the amount of product given daily in treatment. Specifically, the patients in test number two required an additional one to two days to achieve full recovery, but only about half the dosage was used in test number two as compared to test number one and three (15ml compared to 30ml in total daily usage).

Appendix 10

Appendix 11

Appendix 12

Appendix 13

Appendix 14

ASAP vs. ACT For The Treatment Of Malaria

Thank you, Chairman Smith, for asking me to compare ABL's engineered, metallic silver nano-sized particles in water (e.g. ASAP 10), with artemisinin-based combination therapies (ACT's) for the treatment of malaria. While ASAP and the ACT's have a few similarities, the ACT's differ in a number of significant ways from ASAP, and depending on the circumstances, ASAP may be far more useful for a variety of public health, medical and humanitarian efforts at home and abroad.

ASAP and artemisinin are similar in that they both have their origins in the traditional medical practices of ancient cultures. Silver was used for its inherent anti-microbial properties by the ancient Egyptians and in the Ayurvedic medicine of India for thousands of years. Artemisinin is a derivative of an ancient Chinese herbal remedy for fevers - a plant called sweet wormwood - and likewise has been used for thousands of years1.

The raw materials from which ASAP is derived are water and silver, both in abundant supply in the US. ABL has access, through Clifton Mining alone, to 33 square miles of mines, representing several million ounces of silver reserves. ABL and Clifton collectively possess the skills and resources needed to produce ASAP from the ground up, without needing to consider implications of foreign trade policies, political instabilities, or interruptions to the flow of raw materials. The basic raw material for the production of artemisinin, on the other hand, is the sweet wormwood plant grown primarily in China and Viet Nam2. Production of the ACT's is thus dependent on the supply of sweet wormwood from these countries, and is vulnerable to interruptions in supply of the plant, crop failures, etc. Raw material supply problems have already caused interruptions in the anticipated supply of some ACT's3.

Once produced, ASAP has a shelf life estimated to be ten (10) years or more. This allows for the storage and stock-piling of ASAP on a large-scale basis. With an increase in production facilities, lead time is not an issue with ASAP. The ACT's and artemisinin on the other hand, have a shelf life of only 2 to 3 years. Long term stock-piling of the ACT's cannot take place and further, the shorter half-life of the ACT's creates the need for strict control of the supply chain to avoid stock outs, waste or improper use4.

ASAP is a broad spectrum anti-microbial with demonstrated effects against a wide variety of organisms including B. subtilis (a surrogate for Anthrax testing), numerous Staphylococcus species (including "flesh eating bacteria"), E. coli, Salmonella, bovine tuberculosis (a surrogate for human tuberculosis testing), and various fungi and viruses. ASAP has also been used in the treatment of both complicated and uncomplicated malaria and after traditional antimalarial drugs failed, even in babies as previously described. The broad spectrum of ASAP makes it an ideal agent for a variety of anti-microbial uses, providing almost unparalleled flexibility for health care planning and logistics. The ACT's, however, are indicated only for the treatment of malaria (and in some instances only for the treatment, for example, of uncomplicated falciparum malaria) and cannot be stock-piled for other alternative uses.

Once administered, ASAP's engineered, metallic silver nano-sized particles function as single agent, medicinal catalysts with no known side effects. ACT's conversely, are, by definition, combination therapies and use two or more anti-malarial agents at the same time, many of which cause side effects in up to 40% of patients such as dizziness, headache, abdominal pain, loss of appetite, nausea, vomiting, or diarrhea4.

While the cure rates at 14 days are similar5 for ASAP (100%) and the best of the recently tested ACT's (artemether-lumefantrine at 99%, with amodiaquine - artesunate a distant second at 89%), the higher incidence of side effects with ACT's may significantly impact their use as prophylactics against malaria. Based on available clinical data, it is anticipated that small daily doses of ASAP can be taken long term without side effects for malaria prophylaxis. Currently, travelers and residents in high risk malaria areas rarely use traditional or ACT long term prophylaxis, mainly due to the side effects and complications from the anti-malarial drugs6.

Much time and attention has already gone into assessing the affordability and financing of ACT's7. The costs of various ACT antimalarial options range from $2.30 to $3.60 per adult treatment and it is anticipated that ACT's are likely to have affordability and pricing problems . Antimalarial treatment costs are a huge burden to countries where malaria is endemic and many African counties spend about one third of their health budget on this single disease.

On the brighter side, current pricing for ASAP is about $2.50 per adult treatment and it is anticipated that there will not be affordability or pricing issues in regards to ASAP, especially for humanitarian efforts such as the treatment of malaria. In addition to the likelihood that the cost of an adult ASAP treatment for malaria is apt to decline as ABL's production and distribution capabilities increase and expand, ASAP is also a broad spectrum anti-microbial and thus burdened nations utilizing this option would no longer find themselves dedicating a significant portion of their health care budgets to a single disease.

Overall, while there are a few similarities between ASAP and the ACT's, the differences between the two make ASAP a viable and realistic adjunct, or even alternative, to the ACT's in the fight against malaria. The ACT's have potential raw material supply problems, have a comparatively short shelf life, are narrow in anti-microbial spectrum, have side effects both during treatment of malarial fever and as prophylaxis, and require dedication of a significant portion of the health care budgets of stricken countries to this single disease, thereby limiting the growth and flexibility of many developing nations.

As a recent addition to the health care armamentarium, ASAP provides another alternative that was previously unavailable. There is an abundant supply of raw materials for ASAP, it has a longer shelf life and is very broad spectrum (having been tested against malaria as well as a variety of other organisms including bacteria, viruses, and fungi). These characteristics make ASAP ideal for stock-piling as a general anti-microbial agent. ASAP has no known side effects and thus far has been well tolerated even in the critically ill, very young, and elderly. It is likely that the price of ASAP for malaria relief efforts will come down as ABL expands its production capabilities and strategic alliances. ASAP and other similar ABL products represent a new alternative for developed and developing nations alike, for improved health and wellness as well as treatment of many diseases.

1 The Journal of the American Botanical Council, HerbalGram, 2004; 64:19-20

2 "The Use of Artemisinin & its Derivatives as Anti-Malarial Drugs", World Health Organization, WHO/MAL/98/1086

3 "Update on world antimalarial drug supply", World Health Organization, Roll Back Malaria Department; Nov. 8, 2004.

4 "Procurement of Artemether-Lumefantrine (Coartem®) Through WHO", World Health Organization, Roll Back Malaria Department.

5 Lancet, 2005;365:1439, 1474-1441, 1481-1483, 1487-1498

6 "Coartem® Monograph", 3rd Edition January 04, Novartis.

7 "Improving the Affordability and Financing of Artemisinin-Based Combination Therapies", Malaria Control Department & Essential Drugs and Midicines Policy Department, World Health Organization, WHO/CDS/MAL/2003.1095.

Download a printable PDF of this Congressional Testimony

Home Products Safety History FAQs Government Approvals Congressional Testimony Testimonials Clinical Studies ASAP and the Environment News and Links About Us